---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-001469"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2024-01-17T23:59:59+00:00"
generated_at: "2026-06-06T22:54:43.082440+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Windtree licenses cardio drugs to Lee's for up to $138M milestones; PM deals restructured

## Summary
- Lee's gets exclusive rights to istaroxime, rostafuroxin, SERCA2a activators in 14 Asian countries for heart failure and cardiogenic shock.
- Windtree eligible for up to $3.1M in pre-development/regulatory milestones and $135.25M in sales milestones, plus low double-digit sublicense income.
- Tiered royalties from low single-digit to low double-digit on net sales, subject to reduction by up to 50% under generic competition.
- PM USA/PMPSA amendments: Windtree pays $500k fixed plus $1.4M milestones, extinguishes quarterly payments.

## SEC filing metadata
- accession: 0001437749-24-001469
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2024-01-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774924001469/0001437749-24-001469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774924001469/wint20240116_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-001469
- JSON: https://secwatch.observer/filing/0001437749-24-001469.json
- Plain text: https://secwatch.observer/filing/0001437749-24-001469.txt

## Key facts
- Material Agreements
  WINDTREE THERAPEUTICS INC /DE/ entered into License, Development and Commercialization Agreement with Lee's Pharmaceutical (HK) Ltd. with Lee's Pharmaceutical (HK) Ltd. valued at up to $3.1 million in potential upfront pre-development, development, clinical, and regulatory miles (effective 2023-01-07).
  - Action: entry
  - Agreement: license
  - Counterparty: Lee's Pharmaceutical (HK) Ltd.
  - Value: up to $3.1 million in potential upfront pre-development, development, clinical, and regulatory miles
  - Effective: 2023-01-07
  source text: On January 12, 2024 Windtree Therapeutics, Inc. (the “ Company ”) entered into a License, Development and Commercialization Agreement with Lee’s Pharmaceutical (HK) Ltd., a company organized under the laws of Hong Kong (“ Lee ’ s ”), effective as of January 7, 2023 (the “ Lee ’ s License Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774924001469/0001437749-24-001469-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.